DGAP-News: BRAIN AG appoints experienced corporate finance specialist to the Board of Management


DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG /
Key word(s): Change of Personnel
BRAIN AG appoints experienced corporate finance specialist to the Board of
Management

26.09.2016 / 08:30
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

PRESS RELEASE

BRAIN AG appoints experienced corporate finance specialist to the Board of
Management

  - Frank Goebel appointed to the Board of Management of BRAIN AG as of 1
    November 2016

  - Eric Marks to leave the Board of Management of BRAIN AG for personal
    reasons as of 31 October 2016

  - BioIndustrial Segment to be expanded in a consistent manner

  - M&A activities to become the direct responsibility of the BRAIN Group's
    Board of Management

Zwingenberg, 26 September 2016: Changes to the Board of Management and the
management team were pushed forward at the ordinary meeting of the
Supervisory Board of B.R.A.I.N. Biotechnology Research and Information
Network AG ("BRAIN AG"; ISIN DE0005203947 / WKN 520394) on 23 September
2016. Frank Goebel (46) will be appointed to the Board of Management of
BRAIN AG as per 01 November 2016, thus moving from the position of Managing
Director of BRAIN Capital GmbH, which he has held since February 2015, to
the Group Board of Management. This step will anchor the group's M&A
activities, which are crucial for the company's forward integration,
directly in the group's Board of Management.

The creation or expansion of direct ways to access the B2B market as well
as the establishment or extension of sales expertise are building blocks
intended to promote the company's industrialization strategy and to tap
growth opportunities in the BioIndustrial B2B product business. Besides the
group's M&A activities, Frank Goebel will also take over responsibility for
corporate investment management, i.e. the management of the BRAIN Group's
subsidiaries, in order to facilitate an interconnection of the various
subsidiaries' management and thus make even more use of the synergy
potentials within the corporate portfolio. "I am eagerly anticipating this
exciting new challenge. In the past two years, I have already been able to
gain a comprehensive view of the company, and I do see a clear potential
for growth. In future, I would like to cooperate even more closely with our
subsidiaries in order to continuously expand the industrialization of the
BRAIN Group," says Frank Goebel, designated member of BRAIN AG's Board of
Management. Adds Dr Jürgen Eck, CEO of BRAN AG: "I am looking forward to
working together with Frank Goebel, with whom the Board of Management and I
have cooperated in a very trusting and efficient manner in the past."

Eric Marks (55), the enzyme specialist and corporate COO, will leave the
Board of Management as of 31 October 2016 for personal reasons and at his
own request. Says Dr Jürgen Eck, CEO of BRAIN AG: "On behalf of the entire
BRAIN team, I would like to express my thanks for the close and trustful
cooperation. We regret Eric Marks's resignation from the Board of
Management, but respect his decision. Eric Marks has rendered valuable
services to the company when it came to the successful marketing and sales
of products. On the basis created by Mr Marks and making good use of the
industrial network expanded by his efforts, we will continue to further
drive product development and sales in close cooperation with the managing
directors of the companies in the BRAIN Group, thus further growing BRAIN's
BioIndiustrial segment as scheduled. The forming of strategic industrial
partnerships with manufacturers and consumer goods companies, such as the
one recently formed with Roquette in the field of natural sweeteners (DOLCE
programme) will gain in importance as regards product-related business
development and as well as the manufacturing and sale of products in the
B2B business.

The position of Dr Georg Kellinghusen, whose time on the Board of
Manangement was originally limited to 31 December 2016, has been prolonged
until the end of the ordinary shareholders' meeting scheduled for the end
of March 2017, in order to finalize the business year 2015/16 properly.
Afterwards, Frank Goebel will also take over CFO responsibility from Dr
Kellinghusen.

+++END+++


About Frank Goebel

Frank Goebel joined the BRAIN Group as managing director of the company's
wholly-owned subsidiary B.R.A.I.N. Capital GmbH in February 2015 to support
BRAIN's industrialisation strategy. Frank Goebel has a diploma in business
administration and completed all three levels of the CFA programme.  Before
joining BRAIN, Frank Goebel spent 15 years in banking in the Structured
Finance area, the last ten years at the Royal Bank of Scotland plc. working
out of Frankfurt and London. During his earlier years in banking he focused
on LBOs backed by Financial Sponsors, working on widely syndicated
arranging mandates. For the last six years he became involved with
financial restructuring transactions such as debt-for-equity swaps, acting
as an Investment Director on a Pan-European basis. In his early career,
Frank Goebel worked as a controller in a German industrial company as well
as in his father's trading business.

About BRAIN

BRAIN AG is one of Europe's leading technology companies in the field of
industrial biotechnology, the core discipline of the bioeconomy. As such,
BRAIN identifies previously untapped, efficient enzymes, microbial producer
organisms or natural substances from complex biological systems that can be
put to industrial use. The innovative solutions and products developed by
help of this "Toolbox of Nature" are successfully applied in the chemistry,
the cosmetics and the food industries. Today, BRAIN's business model is
based on two pillars - "BioScience" and "BioIndustrial". The first pillar,
"BioScience", comprises its - frequently exclusive - collaboration business
with industrial partners. The second pillar, "BioIndustrial", comprises the
development and commercialisation of BRAIN's own products and active
product components. You will find further information at www.brain-
biotech.de/en.


Contact:

B.R.A.I.N. 
Biotechnology Research
And Information Network AG
Dr. Martin Langer
Executive Vice President
Corporate Development
Darmstädter Str. 34-36
64673 Zwingenberg, Germany

Tel.: +49-(0)-6251-9331-16
Fax.: +49-(0)-6251-9331-11
E-Mail: ml@brain-biotech.de
www.brain-biotech.de


Disclaimer

This press release contains forward-looking statements. These statements
reflect the current views, expectations, and assumptions of the management
of BRAIN AG and are based on information currently available to the
management. Forward-looking statements are not guarantees of future
performance and involve known and unknown risks and uncertainties that
could cause actual results, performance or events to differ materially from
those expressed or implied in such statements. There are numerous factors
which could influence the future performance by and future developments at
BRAIN AG and the BRAIN group. Such factors include, but are not limited to,
changes in the general economic and competitive environment, risks
associated with capital markets, currency exchange rate fluctuations,
changes in international and national laws and regulations, in particular
with respect to tax laws and regulations, and other factors. The company
does not undertake any obligation to update or revise any forward-looking
statements.


---------------------------------------------------------------------------

26.09.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de

---------------------------------------------------------------------------

   Language:    English                                                    
   Company:     B.R.A.I.N. Biotechnology Research And Information Network  
                AG                                                         
                Darmstädter Straße 34-36                                   
                64673 Zwingenberg                                          
                Germany                                                    
   Phone:       +49 (0) 62 51 / 9331-0                                     
   Fax:         +49 (0) 62 51 / 9331-11                                    
   E-mail:      ir@brain-biotech.de                                        
   Internet:    www.brain-biotech.de                                       
   ISIN:        DE0005203947                                               
   WKN:         520394                                                     
   Listed:      Regulated Market in Frankfurt (Prime Standard); Regulated  
                Unofficial Market in Berlin, Dusseldorf, Munich,           
                Stuttgart, Tradegate Exchange                              
 
 
   End of News    DGAP News Service  
---------------------------------------------------------------------------

505255 26.09.2016